Clinical and Aberrometric Outcomes of a New Implantable Collamer Lens for Myopia and Presbyopia Correction in Phakic Patients

PURPOSE: To assess the clinical and aberrometric outcomes of a new Implantable Collamer Lens (EVO Viva ICL; STAAR Surgical) to correct moderate to high myopia and presbyopia. METHODS: The study included 80 eyes of 40 patients who had bilateral EVO Viva ICL implantation. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, presbyopic add power, binocular through-focus visual acuity, total ocular spherical aberration (SA), coma aberration, and root mean square of ocular higher order aberrations (RMS HOAs) (i-Trace Aberrometer; Tracey Technologies) for a 4.5-mm pupil size were evaluated. RESULTS: The mean binocular postoperative UDVA and CDVA were 0.09 +/- 0.19 and 0.02 +/- 0.03 logMAR, respectively. The postoperative spherical equivalent was-0.61 +/- 0.54 diopters (D). The presbyopic add power reduced from +1.31 +/- 0.74 D preoperatively to +0.44 +/- 0.58 D after surgery (P < .0001). The mean visual acuity was 0.1 logMAR or better (20/25 or better) across the vergence range from +0.50 to-1.50 D, better than 0.2 logMAR (20/32 or better) up to the vergence of-2.00 D, and remained better than 0.3 logMAR (20/40 or better) up to the vergence of-2.50 D. The total ocular aberrations induced by EVO Viva ICL were-0.34 +/- 0.09 mu m of SA, 0.24 +/- 0.18 mu m of coma, and 0.26 +/- 0.12 mu m of RMS HOAs. CONCLUSIONS: The outcomes support that the new ICL might be a good alternative for myopia and presbyopia correction in patients aged between 45 and 55 years. Further studies are needed to evaluate the threshold lens misalignment from which the patient<acute accent>s visual quality would be affected.